Pharmaceuticals Analysts discuss Aldeyra Therapeutics’ (ALDX) Reproxalap and its commercial potential in Dry Eye Disease on an Analyst/Industry conference call to be held on December 13.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>